Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation (NCT05890027), a na phase 4 study. The primary outcome is Mean MRD1 After Phenylephrine.

2. Clinical Question

The study concerns people with ptosis, or drooping of the upper eyelid, being evaluated for surgical upper eyelid repair. Its central practical question is whether phenylephrine can serve as an indicator of the effect of lifting the eyelid, in comparison with traditional eyelid taping. The registry describes superior visual field testing under both conditions and also lists satisfaction outcomes.

These are related but not identical questions. The stated primary outcome is a mean measurement after phenylephrine; it is not itself a direct numerical comparison of visual field results under phenylephrine and taping. Satisfaction after each approach and the change in satisfaction are listed as secondary outcomes. The registry record does not report the results for these outcomes, so it is not possible to assess how the observed measurements or participant ratings addressed the study aim.

3. Trial Design

The registry identifies this as a Phase 4 study with a sequential model and no masking. Allocation is listed as not applicable, and the record notes that this is not a randomized comparison. It therefore should not be interpreted as a randomized trial with independent treatment arms serving as like-for-like controls.

The arm description places participants in a single sequence: superior visual field testing is performed with the upper eyelid manually taped first, followed by testing after phenylephrine 2.5% ophthalmic solution. Participants are described as being in each condition for up to 60 minutes. Because the order is fixed in the description, the contrast between conditions can include differences related to timing or order as well as differences between the procedures. The registry does not report an analysis that addresses those possibilities.

The record lists an enrollment of 18 and a completed status. The recorded study start is 2024-03-19, and the primary completion date is 2025-04-01. These are registry entries, not evidence that results for every planned endpoint are available. The record lists 11 outcome measures, including the primary MRD1 endpoint and satisfaction measures, but no analysis entries are reported.

The registry record does not report a statistical analysis plan, a sample-size justification, or an interim analysis plan. The design description alone does not establish how outcomes were analyzed, whether all enrolled participants contributed to each endpoint, or how any missing measurements were handled. Those details should not be inferred from the sequential structure or the completed status.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: This study used an eye-based unit of analysis, where each eye with ptosis served as an individual study unit. Participants with bilateral ptosis contributed two eyes to the study, while those with unilateral ptosis contributed one eye. This was a single-arm study in which all recruited eyes progressed sequentially through identical interventions and assessments as described in the Arm/Group Description.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Mean MRD1 After Phenylephrine, measured over 10 minutes after phenylephrine instillation..

The primary endpoint is mean MRD1 after phenylephrine. MRD1, or Margin to Reflex Distance 1, is a measurement in millimeters. The registry describes measuring it at least 10 minutes after a single drop of 2.5% phenylephrine ophthalmic solution is placed into the superior conjunctival fornix. The stated timeframe is 10 minutes after instillation.

As a continuous measure, MRD1 can be described by a mean, which represents the average observed measurement, and a standard deviation, which describes how spread out individual measurements are around that mean. The registry specifies the mean and standard deviation as the endpoint summary. Neither the mean nor its standard deviation is reported in the registry record.

In general, an eyelid-position measurement can characterize the physical response after the drop, while visual field testing addresses the study's broader interest in the effect of a drooping eyelid on vision. Those are different kinds of information. MRD1 after phenylephrine may describe the measured eyelid position under that condition, but the primary endpoint as stated does not directly quantify a difference in visual field between phenylephrine and taping. The registry record does not report a primary endpoint result or an estimated comparison between the two approaches.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods help distinguish what was measured, what was estimated, and how uncertain an estimate may be. For this study, the registry identifies a continuous primary endpoint: mean MRD1 after phenylephrine. It specifies standard deviation as the measure of dispersion. However, it does not report the endpoint's observed mean or standard deviation, and it lists no analysis entries. The concepts below explain how such methods are generally interpreted; they are not a description of analyses documented for this study.

What does a mean describe?

In general, a mean is the arithmetic average of measurements in the analysis group. It offers a concise description of the center of a continuous outcome, but it does not show every participant's measurement or the full shape of the data. The standard deviation describes the spread of measurements around the mean. A larger spread indicates more variation among measurements relative to the mean; a smaller spread indicates measurements are more concentrated. These summaries answer different questions: the mean concerns the central value, while the standard deviation concerns variability.

A mean alone does not communicate its precision as an estimate of a broader population value. Confidence intervals are commonly used for that purpose. In general, a confidence interval gives a range of values compatible with the data and the assumptions of the analysis, with its width reflecting uncertainty. A narrow interval indicates greater precision than a wide interval under the same interpretive framework. No confidence interval for MRD1 is reported in the registry record, so its precision cannot be assessed.

What would a comparison require?

The protocol description places each participant through taping first and phenylephrine afterward. In general, when two measurements come from the same participant, a paired analysis focuses on within-participant differences. It accounts for the fact that measurements from the same person tend to be related. Treating paired measurements as if they came from unrelated participants can misrepresent the variability relevant to the comparison.

The recorded order also matters. Since taping precedes phenylephrine in the description, a difference between conditions could reflect the procedure, the passage of time, repeated testing, or some combination. A statistical method cannot automatically remove these design concerns. The record does not report an analysis plan, an order-effect assessment, or a model used for repeated observations. It is therefore not possible to say how the posted analysis handled these issues.

The primary endpoint is a mean after phenylephrine, rather than a stated paired difference between phenylephrine and taping. That endpoint can describe the measurement after phenylephrine if results are reported. It does not, on its own, estimate the comparative effect of phenylephrine versus taping. The study's broader visual-field objective and the primary MRD1 outcome should therefore be kept conceptually separate.

How should hypothesis tests be read?

In general, a hypothesis test evaluates how compatible the observed data are with a specified null model, under assumptions about the data and the analysis. A p-value is not the probability that the null hypothesis is true, nor is it a measure of the size or clinical importance of a difference. A small p-value can coexist with a small effect, and a large p-value does not prove that two conditions are equivalent. Effect estimates and confidence intervals are needed to understand magnitude and precision.

The sample-size assumptions state a two-sided significance level of 0.05. A two-sided test considers departures in either direction, while a significance level sets a threshold used in a planned testing procedure. This stated planning assumption is not evidence that a particular test was conducted or that a p-value was calculated. No test statistic, p-value, or confidence interval is reported in the registry record.

What do planning calculations mean?

The sample-size assumptions describe planning illustrations based on the observed effect, with equal allocation between two arms and a normal approximation. The effect to detect is expressed as a stated fraction of the observed effect. Such calculations ask, under their assumptions, how many participants per arm might be needed for a target power level. They are planning illustrations, not the number enrolled in this sequential study and not observed power.

Power is a property of a planned test under a specified effect and assumptions; it is not a retrospective measure of whether a completed study has proved a result. Planning based on an observed effect can also depend strongly on how stable that effect estimate is. The observed effect magnitude and computed planning counts are not reported in the registry record, so no specific count can be interpreted. The registry also does not report the trial's own sample-size justification, and the planning assumptions should not be mistaken for that justification.

Why can over-dispersion matter?

In general, over-dispersion occurs when outcome variation is greater than a statistical model assumes. If a model understates variability, standard errors may be too small and intervals too narrow; tests can then appear more certain than warranted. The primary MRD1 measure is continuous, and the registry specifies a mean and standard deviation, but it does not report a model or evidence of over-dispersion. This is a general statistical consideration, not a finding about these data.

Because the numerical outcome results and analysis details are absent, the statistical methods cannot be checked against the data. Interpretation should remain limited to the endpoint definition, design description, and planning assumptions that are actually documented.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 11 outcome measures, including the primary mean MRD1 after phenylephrine and secondary outcomes for participant satisfaction after taping, after phenylephrine, and the change between those satisfaction scores. When a study assesses multiple outcomes or makes multiple comparisons, the chance of at least one apparently unusual result can increase. Statistical approaches to multiplicity can include designating a primary outcome in advance, adjusting testing thresholds, or treating secondary analyses as exploratory. These are general options; the registry record does not report a multiplicity strategy.

The record identifies a primary outcome, but it does not provide an analysis plan explaining how the other measures were prioritized or tested. No analysis entries are listed, and numerical results for the listed outcomes are not reported. It is therefore not possible to determine whether multiplicity adjustments were made or how any secondary findings should be interpreted relative to the primary endpoint.

Missing-data handling is not reported in the registry record. There is no stated method for handling unavailable measurements, incomplete testing, or missing satisfaction responses. The record also does not report endpoint-specific analysis populations, exclusions, or the number of participants contributing to each outcome. The enrollment of 18 should not be treated as the analysis count for every endpoint without those details.

Likewise, the registry does not report whether analyses followed an intention-to-treat, per-protocol, or other population definition. These omissions limit reproducibility and make it difficult to judge whether the analysis population matches the intended study question. They should be understood as reporting gaps, not evidence that data were missing or that a particular method was or was not used.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event record lists the group as All Study Participants, with 18 at risk for serious adverse events and 0 affected. It also lists 18 at risk for other adverse events and 0 affected, and records 0 deaths. These are the posted counts for the categories represented in the registry record.

Zero recorded events in these categories means that the registry reports no affected participants for the stated counts. It does not establish that an intervention is free of risk. Event counts can be interpreted only alongside information about how events were defined, collected, monitored, and reported, as well as the amount of observation. The registry record does not provide those details in the registry record.

The study describes each participant as being in each condition for up to 60 minutes, but that description should not be treated as a complete account of safety follow-up. The record does not report additional follow-up duration, event ascertainment procedures, or whether all participants had the same opportunity for event reporting. The reported zero counts should therefore be read narrowly as registry-recorded figures, not as proof that no adverse effects occurred under any circumstances.

12. What the Result Does, and Does Not, Mean

The registry record defines a study intended to compare phenylephrine with eyelid taping during evaluation for upper eyelid repair. It describes a sequential procedure in which participants are tested with taping before receiving phenylephrine, and it identifies mean MRD1 after phenylephrine as the primary endpoint. It also lists satisfaction outcomes and adverse-event counts.

What the record does not establish is the observed primary endpoint value, a direct estimate of the difference between conditions, or the precision of such an estimate. No outcome results or analysis entries are reported. Without these, readers cannot judge the magnitude or direction of any observed difference, whether a result was statistically compatible with a range of effects, or how consistently participants responded.

The sequence also limits what a comparison can mean. As a general design consideration, measurements collected in a fixed order can be affected by order, timing, and repeated testing, in addition to the condition being assessed. The registry does not report a method that separates those influences. The study's description should therefore not be interpreted as evidence from a randomized comparison.

The zero adverse-event counts are likewise limited to what the registry records. They do not demonstrate absence of risk or settle safety questions. The completed status and enrollment describe administrative and study-record details, but they do not supply missing results or establish that every listed outcome has a complete analysis.

In general, a study can inform a clinical question most clearly when the outcome estimate, its uncertainty, the analysis population, and the analysis method are reported together. Those details are not available for the outcomes. The appropriate interpretation is consequently descriptive: the registry documents the planned evaluation and selected record-level counts, while the statistical result of the comparison remains unreported.

13. Why This Trial Matters Statistically

This study raises a useful statistical distinction between a physiological measurement and a comparative evaluation. MRD1 after phenylephrine describes an eyelid measurement under that condition. The broader aim concerns whether phenylephrine can indicate the effect assessed through visual field testing in comparison with taping. A single-condition mean and a between-condition comparison answer different questions, so clear alignment between the primary endpoint and the study aim is important.

The sequential, within-participant description also highlights the value of matching analysis to design. Repeated observations on the same participant are generally correlated, and fixed order can introduce interpretive complications. These issues affect the uncertainty and meaning of a comparison, not just the choice of a statistical test. Reporting the order, analysis approach, and relevant assumptions helps readers understand what a contrast can support.

Finally, this record illustrates why estimates and precision matter alongside a study's completed status. Enrollment and event counts do not reveal the size or uncertainty of an endpoint result. Outcome summaries, analysis populations, missing-data methods, and multiplicity procedures are needed to evaluate how strongly the evidence addresses the stated question. Those results and details are not reported in the registry record.

The planning assumptions also underline a common distinction: sample-size calculations are conditional illustrations, not observed evidence. A calculation based on an effect size and chosen assumptions cannot substitute for a reported estimate from the study. These methodological points are broadly relevant to clinical research that compares approaches measured repeatedly in the same participants.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most direct limitation of the available registry information is that it contains no numerical outcome results or analysis entries. The primary endpoint is defined, but its mean and standard deviation are not reported. No direct estimate comparing the taped and phenylephrine conditions, confidence interval, or test result is reported either. This prevents assessment of effect magnitude and precision.

The design description specifies the order of conditions: taping first, then phenylephrine. This is not a randomized allocation, and the record explicitly cautions against treating the arms as a like-for-like control comparison. In general, fixed order can make condition differences difficult to separate from timing or repeat-testing effects. The registry does not describe an analysis addressing these considerations.

Further details needed to assess the results are not reported in the registry record. These include endpoint-specific analysis counts, missing-data handling, analysis-population definitions, a detailed statistical analysis plan, and a multiplicity strategy. The record does not provide a sample-size justification for the trial. The planning assumptions described in the sample-size material should not be substituted for one.

The safety information is also limited to the reported event counts. The record does not detail event definitions, collection procedures, or the duration and completeness of safety follow-up. These limitations concern what can be concluded from the registry record; they do not establish that the underlying study lacked procedures or analyses that were not recorded.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation — NCT05890027.
• Registry record last updated 2025-08-22; status last verified 2025-08.
• Results first posted 2025-08-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed Phase 4 study of phenylephrine versus eyelid taping for evaluation of Muller's Muscle-Conjunctival Resection. It lists an enrollment of 18, a sequential model, no masking, and allocation as not applicable. Participants are described as receiving superior visual field testing with the eyelid taped before testing after phenylephrine 2.5% ophthalmic solution.

The primary endpoint is mean MRD1, measured at least 10 minutes after phenylephrine administration. Participant satisfaction after taping, after phenylephrine, and the change in satisfaction are listed as secondary outcomes. The registry lists 11 outcome measures, but no analysis entries or numerical outcome results are reported.

For the all-participant group, the record lists 0 serious adverse events, 0 other adverse events, and 0 deaths. These counts do not establish absence of risk. The record documents the study question and selected design and safety details, but does not provide enough outcome or analysis information to evaluate the statistical result of the comparison.